Psychiatric aspects of designer drugs and new psychoactive substances consumption
Vladimir Valerievich Mrykhin, Andrey Viktorovich Antsyborov
Interactive science February 22, 2017 DOI: 10.21661/r-116849 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Designer drug Psychoactive substance Consumption sociology Mephedrone Social science |
| Citations | 2 |
| Key findings | New psychoactive substances affect multiple neurotransmitter pathways and receptors, and their use can lead to polymorphic psychotic disorders. |
Abstract
According to the authors, appeared not long ago new psychoactive substances (designer drugs), including synthetic cannabinoids, derivatives of cathinone, phenethylamines, new stimulants, synthetic opioids, tryptamine derivatives, phencyclidine, piperazine, agonists of GABA (A/B) receptors have become a serious problem for both consumers and doctors. Consumers of these substances are attracted primarily by the intensity of psychoactive effects, as well as «legal purity», which is declared by shadow producers. This indicates that there are some significant difficulties of laboratory typing of new surfactants. Designer drugs when ingested, can affect a range of neurotransmitter pathways/receptors: dopamine, cannabinoid (CB1), GABA(A/B), 5-HT2A, glutamate, and k-opioid receptors (KOR), the imbalance of which leads to the development of polymorphic psychotic disorders.